ArticlePLoS pathogens2026
Structural basis of a conserved, broad antigenic region surrounding the five-fold axis of foot-and-mouth disease virus revealed by swine neutralizing antibodies.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Foot-and-mouth disease virus (FMDV) exhibits extensive antigenic diversity and limited cross-protection among different serotypes, making the identification of broadly neutralizing antibodies (bnAbs) critical for the development of vaccines that confer broad and effective protection. Here, we isolated four porcine-derived bnAbs that broadly neutralized multiple representative strains from FMDV serotypes O and A. These bnAbs convergently target a conserved antigenic region, with residue 204 (K) towards the VP1 C-terminus serving as a key determinant. Notably, the bnAb pO18-10, which competes with antibodies recognizing the VP1 G-H loop, VP1 C-terminus, and VP3 epitopes, exhibits the broadest neutralization breadth, including cross-neutralization against serotype Asia1. Cryo-electron microscopy (cryo-EM) of pO18-10 in complex with FMDV serotype O (O/18074) revealed a novel cross-protomer antigenic region located around the icosahedral five-fold axis of the viral capsid, with an interaction footprint of up to 1452 Ų. pO18-10 engages this epitope through interactions with the VP1 C-terminus and VP3 G-H loop of one protomer, as well as the VP1 E-F loop of an adjacent protomer, demonstrating extensive antigenic coverage. Residues 204 (K) and 210 (K) on VP1 were identified as key determinants of this cross-serotype antigenic site. Furthermore, pO18-10 sterically blocks the integrin receptor αvβ6, effectively neutralizing FMDV by preventing viral attachment. In vivo, pO18-10 conferred robust prophylactic and therapeutic protection against FMDV-induced mortality and clinical disease in mice. Collectively, these findings provide a promising neutralizing antibody candidate for immunodiagnostic applications and define a cross-serotype antigenic structure for universal FMDV vaccine design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.